A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Branch Retinal Vein Occlusion
NCT ID: NCT00308477
Last Updated: 2012-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
NCT00168324
A Study of the Safety and Efficacy of SK-0503 for Diabetic Macular Edema
NCT00308542
A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion
NCT00168298
Intravitreal Dexamethasone Implant for Refractory Diabetic Macular Edema:
NCT05847088
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
NCT04120311
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dexamethasone
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The criteria for visual acuity and macular thickness are met
Exclusion Criteria
* Diabetic retinopathy
* Known steroid-responder
* Use of systemic steroids
* Use of Warfarin/Heparin
20 Years
79 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sanwa Kagaku Kenkyusho Co., Ltd.
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Study Group, Clinical Development Dept.
Role: STUDY_DIRECTOR
Sanwa Kagaku Kenkyusho Co., Ltd.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Aichi, , Japan
Chiba, , Japan
Fukuoka, , Japan
Gunma, , Japan
Hokkaido, , Japan
Kagawa, , Japan
Kyoto, , Japan
Mie, , Japan
Miyazaki, , Japan
Osaka, , Japan
Shiga, , Japan
Tokyo, , Japan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DX4001
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.